文献速递血脂与心血管预防

肝脏感知环路调控PCSK9分泌以响应抑制性抗体

Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

本研究探讨PCSK9抑制剂治疗后血浆PCSK9水平大幅升高的机制。在临床队列、动物模型和细胞研究中,发现PCSK9抑制剂使血浆PCSK9升高,部分源于PCSK9分泌的翻译后增加,而非仅由清除延迟所致。PCSK9经LDLR再入肝触发感知环路调控其分泌。

要点

  • PCSK9抑制剂使血浆PCSK9升高,部分因分泌增加而非仅清除延迟
  • PCSK9经LDLR再入肝触发感知环路调控PCSK9分泌
  • 该机制依赖LDLR存在,动物模型验证

核心结论

  • PCSK9经LDLR再入肝触发感知环路调控PCSK9分泌,PCSK9抑制剂增强PCSK9分泌,贡献于治疗者血浆PCSK9升高。

研究设计与样本

  • 临床队列、动物模型和细胞研究,测量PCSK9抑制剂后PCSK9产生和清除的动力学变化。

主要发现

  • 接受PCSK9抑制剂治疗的患者队列中,血浆PCSK9水平前3个月升高11倍,随后15个月 plateau。
  • 健康志愿者单次注射PCSK9抑制剂后12小时内血浆PCSK9升高,持续9天至基线10倍后 plateau。
  • 小鼠模型重现PCSK9快速升高,但仅在LDLR存在时。
  • 体内周转和体外 pulse-chase 研究识别两个机制:抗体结合的PCSK9清除延迟和PCSK9分泌的翻译后增加。

临床怎么用

  • 理解PCSK9抑制剂升高血浆PCSK9的机制,部分因分泌增加,有助于解释药物效应和监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Monoclonal antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9i) lower LDL-C by up to 60% and increase plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) levels by 10-fold. OBJECTIVES: The authors studied the reasons behind the robust increase in plasma PCSK9 levels by testing the hypothesis that mechanisms beyond clearance via the low-density lipoprotein receptor (LDLR) contribute to the regulation of cholesterol homeostasis. METHODS: In clinical cohorts, animal models, and cell-based studies, we measured kinetic changes in PCSK9 production and clearance in response to PCSK9i. RESULTS: In a patient cohort receiving PCSK9i therapy, plasma PCSK9 levels rose 11-fold during the first 3 months and then plateaued for 15 months. In a cohort of healthy volunteers, a single injection of PCSK9i increased plasma PCSK9 levels within 12 hours; the rise continued for 9 days until it plateaued at 10-fold above baseline. We recapitulated the rapid rise in PCSK9 levels in a mouse model, but only in the presence of LDLR. In vivo turnover and in vitro pulse-chase studies identified 2 mechanisms contributing to the rapid increase in plasma PCSK9 levels in response to PCSK9i: 1) the expected delayed clearance of the antibody-bound PCSK9; and 2) the unexpected post-translational increase in PCSK9 secretion. CONCLUSIONS: PCSK9 re-entry to the liver via LDLR triggers a sensing loop regulating PCSK9 secretion. PCSK9i therapy enhances the secretion of PCSK9, an effect that contributes to the increased plasma PCSK9 levels in treated subjects.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Oleaga C, Shapiro MD, Hay J, et al. Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies. J Am Coll Cardiol. 2021. PMID: 34593126. doi:10.1016/j.jacc.2021.07.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。